Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alexander C. Sapir
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Beta
- 3.00
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 10.30
Financials
Revenue
$0.00-100.0%Net Income
$-26.18MEBITDA
$-19.69MFree Cash Flow
$-16.15MEPS (diluted)
$-0.34Shares Outstanding (diluted)
76.26M+350.2%Operating Expenses
$19.91MCash & Debt
$318.84MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-74.88M | $-1.18 |
| 2024 | $80.00M | $-9.72M | $-0.16 |
| 2023 | $2.81M | $-97.33M | $-1.59 |
| 2022 | $6.34M | $-109.87M | $-2.35 |
| 2021 | $19.16M | $-80.85M | $-2.22 |
| 2020 | $8.82M | $-70.82M | $-2.70 |
| 2019 | $0.00 | $-82.68M | $-3.49 |
| 2018 | $0.00 | $-32.59M | $-1.92 |
| 2017 | $0.00 | $-22.96M | $-1.36 |
Valuation
FULChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
40+0.00%Social Signal Score
Mentions (17)
- Newsnewsfilecorp.com·6d ago·Negative
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations New York, New York--(Newsfile Corp. - September 30, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have informa…
View source ↗ - Newsnewsfilecorp.com·8d ago·Negative
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Pending Securities Investigation New York, New York--(Newsfile Corp. - September 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that cou…
View source ↗ - Newsnewsfilecorp.com·11d ago·Negative
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors: The Firm is Investigating Possible Securities Law Violations New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you hav…
View source ↗ - Newsnewsfilecorp.com·13d ago·Negative
Kaplan Fox Broadens its Investigation of Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have informat…
View source ↗ - Newsnewsfilecorp.com·21d ago·Negative
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Investors Who Suffered Losses New York, New York--(Newsfile Corp. - September 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could ass…
View source ↗ - Newsbusinesswire.com·30d ago·Negative
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Slate Medicines, Inc. Upon closing of the proposed transaction, Fulcrum shareholders are expected to own 5.0% of the combined company.Halper Sadeh encourages Fulcrum shareholders to click here to learn more about th…
View source ↗ - Newsnewsfilecorp.com·31d ago·Negative
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) on Behalf of Shareholders for Possible Securities Law Violations New York, New York--(Newsfile Corp. - September 4, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you h…
View source ↗ - Newsnewsfilecorp.com·35d ago·Negative
Kaplan Fox Notifies Investors of Fulcrum Therapeutics, Inc. (FULC) of a Securities Law Investigation New York, New York--(Newsfile Corp. - August 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could a…
View source ↗ - Newsnewsfilecorp.com·40d ago·Negative
Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (FULC) to a Securities Law Investigation New York, New York--(Newsfile Corp. - August 26, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could ass…
View source ↗ - Newsnewsfilecorp.com·42d ago·Negative
Kaplan Fox Announces an Investigation into Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could as…
View source ↗ - Newsnewsfilecorp.com·49d ago·Negative
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Potential Violations of the Federal Securities Laws New York, New York--(Newsfile Corp. - August 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have informa…
View source ↗ - Newsmarketbeat.com·50d ago·Negative
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal Fulcrum Therapeutics NASDAQ: FULC has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions.
View source ↗ - Newsbusinesswire.com·50d ago·Negative
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) and Slate Medicines, Inc. Upon closing of the proposed transaction, Fulcrum shareholders are expected to own 5.0% of the combined company. Halper Sadeh encourages Fulcrum shareholders to click here to learn more about t…
View source ↗ - Newsreuters.com·50d ago·Negative
Fulcrum to merge with Slate in all-stock deal after drug setback Fulcrum Therapeutics said on Monday it would merge with privately held Slate Medicines in an all-stock deal, as the biotech looks to rebuild its pipeline after it discontinued development of its lead drug candidate last month.
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics
View source ↗ - Newsnewsfilecorp.com·52d ago·Negative
Kaplan Fox & Kilsheimer LLP is Investigating Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have informa…
View source ↗ - Newsnewsfilecorp.com·54d ago·Negative
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors for Potential Securities Law Violations New York, New York--(Newsfile Corp. - August 12, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $-0.07 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.34 vs $-0.24miss
- Mon, Apr 27$-0.25 vs $-0.31beat
- Tue, Feb 24$-0.31 vs $-0.31beat
- Wed, Oct 29$-0.31 vs $-0.29miss
- Tue, Jul 29$-0.28 vs $-0.29beat
- Thu, May 1$-0.28 vs $-0.29beat
Estimates and results for FULC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FULC officers and directors.
- Bought
- $42.0m
- Sold
- $59.3m
15 trades
14 trades
- Tang Kevinbought
- Tang Kevinbought
- Tang Kevinbought
- Tang Kevinbought
- Tang Kevinbought
- Tang Kevinbought
- Ezekowitz Alansold
- Gould Robert Jsold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in FULC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.